Enzyme activities in the tibialis anterior muscle of young moderately active men and women: relationship with body composition, muscle cross-sectional area and fibre type composition.
Calponin (4.1-5.9/.tM, pig stomach) inhibited maximal shortening velocity (Vm,x) by 20-25% with only minor influence on force in skinned smooth muscle from guinea-pig taenia coli activated at different Ca 2+ levels and with thiophosphorylation. Similar results were obtained with a fragment of the Nterminal 1-228 amino acids engineered using a mouse cDNA construct (5.4 pM). Both the native calponin and the fragment inhibited actin filament sliding in a graded manner in an in vitro motility assay. We conclude that calponin influences the kinetics of the actin-myosin interaction in the organised smooth muscle contractile system and that engineered fragments of calponin can be used to probe its action in muscle fibres. The effects can be due to an introduction of an internal load during filament sliding, possibly by decreasing the detachment rates and increasing the cross-bridge time spent in the attached state.
We have investigated the effects of vanadate (Vi) on force generation by, and shortening of, chemically skinned smooth muscle preparations from guinea-pig taenia coli at 22 degrees C. A method, using phosphatase inhibitors, was introduced to obtain stable, long-lasting contractions in thiophosphorylated preparations. Vi (10-1000 microM) dose-dependently inhibited active force, to about 20% of its maximum level. At a higher temperature (30 degrees C), the rate of inhibition was faster but the extent of inhibition was less. The rate of contraction following photolytic release of ATP to fibres in rigor was not affected by Vi (30 microM). The maximal shortening velocity (Vmax) was inhibited in a similar manner as active force by Vi (30 microM). In conclusion, the results suggest that Vi interacts with a force-generating actomyosin-ADP (AMADP) state reached after phosphate release. The rate of inhibition of smooth muscle contraction was markedly lower than in skeletal muscle, suggesting differences either in properties of the Vi-bound states or, more likely, in the concentration of AMADP states capable of binding Vi. This suggests that the long duty cycle in smooth muscle is not associated with a higher relative population of AMADP states reached immediately after Pi release, but rather by an increase in the population of subsequent force-generating cross-bridge states. The Vi-bound cross-bridges introduce an internal load to shortening, possibly acting in a similar manner as cross-bridge states introduced at low levels of activation.
BackgroundPatients with Acute Hypercapnic Respiratory Failure (AHRF) who are unresponsive to appropriate medical treatment, are often treated with Noninvasive Positive Pressure Ventilation (NPPV). Clinical predictors of the outcome of this treatment are scarce. Therefore, we evaluated the role of the biomarkers IL-8 and GDF-15 in predicting 28-day mortality in patients with AHRF who receive treatment with NPPV.MethodsThe study population were 46 patients treated with NPPV for AHRF. Clinical and background data was registered and blood samples taken for analysis of inflammatory biomarkers. IL-8 and GDF-15 were selected for analysis, and related to risk of 28-day mortality (primary endpoint) using Cox proportional hazard models adjusted for gender, age and various clinical parameters.ResultsOf the 46 patients, there were 3 subgroup in regards to primary diagnosis: Acute Exacerbation of COPD (AECOPD, n = 34), Acute Heart Failure (AHF, n = 8) and Acute Exacerbation in Obesity Hypoventilation Syndrome (AEOHS, n = 4). There was significant difference in the basic characteristic of the subgroups, but not in the clinical parameters that were used in treatment decisions. 13 patients died within 28 days of admission (28%). The Hazard Ratio for 28-days mortality per 1-SD increment of IL-8 was 3.88 (95% CI 1.86–8.06, p < 0.001). When IL-8 values were divided into tertiles, the highest tertile had a significant association with 28 days mortality, HR 10.02 (95% CI 1.24–80.77, p for trend 0.03), compared with the lowest tertile. This correlation was maintained when the largest subgroup with AECOPD was analyzed. GDF-15 was correlated in the same way, but when put into the same model as IL-8, the significance disappeared.ConclusionIL-8 is a target to explore further as a predictor of 28 days mortality, in patients with AHRF treated with NPPV.
We have studied the temperature dependence of isometric force, rate of force development and maximal shortening velocity (Vmax) in skinned guinea-pig taenia coli smooth muscle. To eliminate the influence of temperature on activation mechanisms, maximally thiophosphorylated preparations were used. Isometric force in the range 2-35 degrees C was maximal at 22 degrees C with a decrease of 25% at 2 degrees C and 10% at 35 degrees C. Rate of tension development from rigor after photolytic release of ATP increased four-fold between 5 degrees C and 30 degrees C. Vmax increased with a Q10 of about 2 (1.6, range 5-15 degrees C, and 2.2, range 22-30 degrees C). The temperature dependence of the rate of tension development indicates rate-limitation by transitions into force-generating states or by the hydrolysis reaction. The temperature dependence of Vmax reflects effects of temperature on reactions (e.g. the ADP-release) associated with cross-bridge detachment. The small temperature dependence of steady-state force in smooth compared with skeletal muscle suggests differences in the cross-bridge reactions controlling the number of attached force-generating states in the two muscle types.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.